The Makings of a Microarray Prognosis

A TELLING EXPRESSION:© 2002 ElsevierExpression patterns for 7 and 20 genes that were selected as discriminators of relapse versus continuous complete remission (CCR) for two types of acute lymphoblastic leukemia, T-ALL and hyperdiploid >50 ALL. (from E-.J. Yeoh et al., Cancer Cell 1:133–43, 2002.)Countless things can go wrong in the complicated cell division process. Checkpoints fail, genomic instability increases, and when anarchy reigns, cancers spread. In trying to assess what is d

Written byBrendan Maher
| 8 min read

Register for free to listen to this article
Listen with Speechify
0:00
8:00
Share

© 2002 Elsevier

Expression patterns for 7 and 20 genes that were selected as discriminators of relapse versus continuous complete remission (CCR) for two types of acute lymphoblastic leukemia, T-ALL and hyperdiploid >50 ALL. (from E-.J. Yeoh et al., Cancer Cell 1:133–43, 2002.)

Countless things can go wrong in the complicated cell division process. Checkpoints fail, genomic instability increases, and when anarchy reigns, cancers spread. In trying to assess what is doing the damage and predict the damage yet to be done, doctors have an admittedly blunt set of tools to profile renegade cells. Histopathology and general prognostic indicators such as health, age, and metastatic spread do little to account for the breadth of tumor variety even within fairly specialized tumor types.

Since researchers first started toying with microarrays, they have considered the molecular profiling of tumors to be an important potential use. The genes that switch on and off ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies